The Investment Dilemma: The “Must-Play” Game of the Era. AI has emerged as the defining strategic priority and a primary target for capital allocation across industries. From pharmaceuticals to retail, companies are aggressively deploying Generative AI and automation at a
Continue Reading
Antibody-Drug Conjugates (ADCs) are among the most promising precision therapies today. By combining the high targeting capability of monoclonal antibodies with the potent cytotoxicity of small-molecule drugs, they have become a new focal point in the R&D of cancer and
Continue Reading
ADC Opportunities and Challenges: High Technical Barriers are the Cornerstone of Long-Term CDMO Advantage. For pharmaceutical CDMOs, ADCs present immense commercial opportunities. On one hand, the rapid expansion of global clinical pipelines is driving outsourcing demand. On the other hand,
Continue Reading
[Taipei, Feb 23] — TherapiAI, a leader in AI-driven pharmaceuticals, announced today the launch of the world’s first GMP AI Agent specifically engineered for Pharmaceutical CDMOs. The agent features advanced RAG (Retrieval-Augmented Generation) capabilities for global regulations, including FDA and
Continue Reading
The wave of AI is accelerating the transformation of the global pharmaceutical industry. AI startup therapiAI announced today (Feb 9) the completion of a Phase 1 AI Proof of Concept (POC) with Panlabs, a world-class leader in biotechnology. Focusing on
Continue Reading
therapiAI, a leading AI pharmaceutical company, announced today the launch of the world’s first AI Agent dedicated to Antibody-Drug Conjugates (ADCs). This technology significantly compresses the traditional 2-3 year R&D exploration phase. By following the AI Agent’s recommendations, researchers can
Continue Reading
Article Categories
Article Categories
Article Categories
Latest Articles
Follow Us
